Trexquant Investment LP cut its stake in Core Laboratories Inc. (NYSE:CLB - Free Report) by 34.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 102,951 shares of the oil and gas company's stock after selling 54,470 shares during the quarter. Trexquant Investment LP owned approximately 0.22% of Core Laboratories worth $1,782,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Disciplined Growth Investors Inc. MN boosted its holdings in Core Laboratories by 26.7% during the third quarter. Disciplined Growth Investors Inc. MN now owns 5,653,591 shares of the oil and gas company's stock worth $104,761,000 after buying an additional 1,192,871 shares in the last quarter. State Street Corp increased its stake in shares of Core Laboratories by 2.9% in the 3rd quarter. State Street Corp now owns 1,975,016 shares of the oil and gas company's stock valued at $36,597,000 after purchasing an additional 56,187 shares in the last quarter. Geode Capital Management LLC raised its holdings in Core Laboratories by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,058,620 shares of the oil and gas company's stock worth $18,329,000 after purchasing an additional 5,416 shares during the period. Boston Trust Walden Corp boosted its position in Core Laboratories by 2.7% during the fourth quarter. Boston Trust Walden Corp now owns 617,336 shares of the oil and gas company's stock worth $10,686,000 after purchasing an additional 16,503 shares in the last quarter. Finally, Van ECK Associates Corp increased its position in shares of Core Laboratories by 6.3% in the fourth quarter. Van ECK Associates Corp now owns 443,621 shares of the oil and gas company's stock valued at $7,679,000 after buying an additional 26,237 shares in the last quarter. Institutional investors and hedge funds own 97.81% of the company's stock.
Wall Street Analyst Weigh In
Separately, Citigroup raised shares of Core Laboratories from a "sell" rating to a "neutral" rating and boosted their price target for the stock from $15.00 to $16.00 in a report on Wednesday, March 12th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the company. According to MarketBeat, Core Laboratories currently has a consensus rating of "Hold" and an average price target of $17.50.
Check Out Our Latest Research Report on CLB
Core Laboratories Price Performance
Shares of NYSE CLB traded up $0.02 during midday trading on Monday, hitting $12.20. The stock had a trading volume of 23,832 shares, compared to its average volume of 383,625. The company has a quick ratio of 1.71, a current ratio of 2.32 and a debt-to-equity ratio of 0.49. Core Laboratories Inc. has a 1 year low of $10.14 and a 1 year high of $25.13. The company has a market capitalization of $569.76 million, a PE ratio of 18.48, a P/E/G ratio of 0.99 and a beta of 1.99. The stock has a 50 day simple moving average of $15.02 and a 200-day simple moving average of $17.65.
Core Laboratories (NYSE:CLB - Get Free Report) last issued its earnings results on Wednesday, January 29th. The oil and gas company reported $0.23 EPS for the quarter, meeting analysts' consensus estimates of $0.23. Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. On average, sell-side analysts expect that Core Laboratories Inc. will post 0.96 EPS for the current fiscal year.
Core Laboratories Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Monday, February 10th were given a $0.01 dividend. The ex-dividend date of this dividend was Monday, February 10th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.33%. Core Laboratories's dividend payout ratio (DPR) is presently 6.06%.
About Core Laboratories
(
Free Report)
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
Further Reading
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
